•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Healthcare Realty: This 5% Yielder Is Still Too Cheap To Ignore
Healthcare Realty Trust Q3 Earnings Call Highlights
Healthcare Realty Trust Incorporated (HR) Q3 2026 Earnings Call Transcript
Compared to Estimates, Healthcare Realty Trust (HR) Q3 Earnings: A Look at Key Metrics
Healthcare Realty Trust (HR) Tops Q3 FFO and Revenue Estimates
Healthcare Realty Reports Third Quarter 2026 Results and Further Increases Full Year 2026 Guidance
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Akamai Technolgies, Apple, Blackrock, Ford Motor, Healthcare Realty Trust, Noble, Sunoco LP, Venture Global, Western Midstream Partners, Zoetis, and More
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
Healthcare Realty Trust Releases Eighth Corporate Responsibility Report
Healthcare Realty Trust Announces Third Quarter Earnings Release Date and Conference Call
Pensionfund PDN Acquires 59,719 Shares of Healthcare Realty Trust Incorporated $HR
Corient Private Wealth LP Purchases 30,584 Shares of Healthcare Realty Trust Incorporated $HR
State Street Corp Reduces Stock Position in Healthcare Realty Trust Incorporated $HR
Down 5.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Healthcare Realty Trust (HR)
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplast
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTIN
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu
Healthcare Realty Trust (HR) Upgraded to Buy: What Does It Mean for the Stock?